DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for conjunctivitis — screening already-approved drugs against its 19-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleConjunctivitis maps to a 19-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for conjunctivitis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FKBP prolyl isomerase 1A (FKBP1A) — FKBP1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4~{s},5~{r},6~{z},9~{s},10~{s},12~{e}drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6I1S · 1.52 Å · ligand (4~{S},5~{R},6~{Z},9~{S},10~{S},12~{E})-16-(ethylamino)-4,5-dimethyl-9,10,18-tris(oxidanyl)-3-oxabicyclo[12.4.0]octadeca-1(14),6,12,15,17-pentaene-2,8-dione (E26). Experimental structure, not a prediction.
What the evidence adds up to
Conjunctivitis is a nonspecific inflammation of the ocular surface and conjunctiva from infectious or noninfectious causes. Infectious conjunctivitis most commonly results from exogenous inoculation of the mucous membranes lining the eye and eyelid, activating a local inflammatory response. The vast majority of acute infectious cases are self-limited and produce few long-term sequelae, though appropriate evaluation and therapy are indicated for specific presentations. Adenoviruses and herpes simplex virus are the most common viral causes. It is sometimes clinically difficult to differentiate viral from bacterial infective conjunctivitis. Bacterial conjunctivitis has a high rate of spontaneous resolution within two to five days; a topical antibiotic is recommended only if there is no improvement or worsening after two to three days.
Historically, virus agents have been notably difficult to isolate and identify, and only a few are known to respond to present antibiotic and chemotherapeutic agents. Cases are still sometimes seen that appear resistant to commonly prescribed therapeutic measures and may carry the additional danger of being caused by easily transmissible pathogenic agents, leading to epidemic outbreaks. Such types of conjunctivitis may be responsible for considerable morbidity and loss of time from schools, offices, and factories. Association with swimming pools or dissemination attributed to ophthalmologists' instruments have been noted.
No specific drug repurposing evidence for conjunctivitis is reported in these abstracts. The papers describe general management and the self-limiting nature of most cases, but they do not test or recommend any particular repurposed drug. What is still missing is any controlled trial data for repurposed agents in conjunctivitis, as well as patient stratification to distinguish viral from bacterial cases at the point of care, and funding to test existing drugs against the specific viral pathogens that cause epidemic outbreaks.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
A M A Archives of Ophthalmology · 1955 · 28 citations
Conjunctivitis in Adenoidal-PharyngealConjunctival Virus Infection
AbstractConjunctivitis is an entity often taken lightly by both the physician and the public. Many causative agents are known, and effective therapy is found for most of them. However, cases are still sometimes seen which not only appear resistant to commonly prescribed therapeutic measures but may have the additional danger that they are caused by easily transmissible pathogenic agents, leading to epidemic outbreaks. Such types of conjunctivitis may be responsible for considerable morbidity and loss of time from schools, offices, and factories. Virus agents are notably difficult to isolate and identify, and only a few are known to respond to present antibiotic and chemotherapeutic agents. In recent years references have been made to conjunctivitis appearing in epidemic form with characteristics suggestive of a viral origin but not fitting into classifications of known virus conjunctivitides. Association with swimming pools or dissemination attributed to ophthalmologists' instruments have in the past been
Cambridge University Press eBooks · 2015 · 3 citations
Conjunctivitis
AbstractConjunctivitis is a nonspecific term used to describe inflammation of the ocular surface and conjunctiva from either infectious or noninfectious causes. Infectious conjunctivitis is most commonly due to exogenous inoculation of the mucous membranes lining the surface of the eye and eyelid, resulting in an activation of a local inflammatory response. The vast majority of cases are acute but it may also present as chronic or recurrent. Although most cases of acute infectious conjunctivitis are self-limited and result in few long-term sequelae, appropriate evaluation and therapy are indicated with specific presentations.
AbstractOverall key points Infective conjunctivitis is a common infection of the mucous membrane on the surface of the eye. Adenoviruses and herpes simplex virus are the most common causes of viral infection. It is sometimes clinically difficult to differentiate between viral and bacterial infective conjunctivitis. There is a high rate of spontaneous resolution of bacterial conjunctivitis, within two-five days. A topical antibiotic is recommended if there is no improvement/worsening after two-three days.
Cambridge University Press eBooks · 2008 · 0 citations
Conjunctivitis
AbstractConjunctivitis is a nonspecific term used to describe inflammation of the ocular surface and conjunctiva from either infectious or noninfectious causes. Infectious conjunctivitis is most commonly due to exogenous inoculation of the mucous membranes lining the surface of the eye and eyelid, resulting in an activation of a local inflammatory response. The vast majority of cases are acute but may also present as chronic or recurrent. Although most cases of acute infectious conjunctivitis are self-limited and result in few long-term sequelae, appropriate evaluation and therapy are indicated with specific presentations.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
